Intensive care for ovarian hyperstimulation syndrome. National clinical recommendations

References

[1] Гинекология: Национальное руководство / под ред. В.И. Кулакова, Г.М. Савельевой, И.Б. Манухина. М.: ГЭОТАР-Медиа, 2009.

[2] Корнеева И.Е. Синдром гиперстимуляции яичников. В кн.: Бесплодный брак / Под ред. В.И. Кулакова. М: ГЭОТАР-Медиa 2006; 449-496.

[3] Корнеева И.Е., Иванова А.В., Баркалина Н.В. Синдром гиперстимуляции яичников: профилактика, диагностика, лечение (обзор литературы). Пробл. репрод. 2004; 10: 1; 43-50.

[4] Краснопольская К.В., Ашхаруа Т.А. Применение селективных стимуляторов дофаминовых D2-рецепторов для профилактики синдрома гиперстимуляции яичников (обзор литературы). Пробл. репрод. 2011; 3; 63-68.

[5] Об утверждении стандарта медицинской помощи больным с гиперстимуляцией яичника: Приказ Минздравсоцразвития России от 02.03.2006 N 134.

[6] Сафронова Е.В. Синдром гиперстимуляции яичников в программе экстракорпорального оплодотворения (прогнозирование, про филактика): Автореф. дис. … канд. мед. наук. Ростов н/Д, 2008; 135.

[7] Шифман Е.М., Погодин О.К., Гуменюк Е.Г. и др. Синдром гиперстимуляции яичников: патогенетическое обоснование интенсивной терапии. Анестезиология и реаниматология. 2007; 4: 33-38.

[8] Щербакова Л.Н. Синдром гиперстимуляции яичников в программе экстракорпорального оплодотворения. Клиническое течение и репродуктивные потери: Автореф. дис. … канд. мед. наук. М., 2010: 157 с.

[9] Aboulghar M. Treatment of ovarian hyperstimulation syndrome. Semin. Reprod. Med. 2010; 28 (6): 532-539.

[10] Bates S.M., Greer I.A., Pabinger I. et al. American College of Chest Physicians. Venous thromboembolism, thrombophilia, anti thrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (6 Suppl.): 844S-86S.

[11] American College of Obstetricians and Gynecologists (ACOG). Inherited thrombophilias in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG) - 2010: 11 p. (Practice bulletin; no. 111).

[12] Baglin T., Gray E., Greaves M. et al. British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br. J. Haematol. 2010; 149 (2): 209-220.

[13] Burke-Gaffney A., Evans T.W. Lest we forget the endothelial glycocalyx in sepsis. Crit. Care. 2012; 16 (2): 121.

[14] ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum. Reprod. Update; 2013.

[15] Federación Mexicana de Colegios de Obstetricia y Ginecología. Prevention, early diagnosis and treatment of ovarian hyperstimulation syndrome. Ginecol. Obstet. Mex. 2011; 79 (11): 732-738.

[16] Donati A., Domizi R., Damiani E. et al. From macrohemodynamic to the microcirculation. Crit. Care Res. Pract. 2013; 2013: 892710.

[17] García-Benítez C.Q., Avilés-Cabrera R.N. Arterial thrombosis in ovarian hyperstimulation syndrome. Ginecol. Obstet. Mex. 2011; 79 (3): 152-155.

[18] Henrich M., Gruss M., Weigand M.A. Sepsis-induced degradation of endothelial glycocalix. Scientific World Journal. 2010; 10: 917-923.

[19] Sansone P., Aurilio C., Pace M.C. et al. Intensive care treatment of ovarian hyperstimulation syndrome (OHSS). Ann. N.Y. Acad. Sci. 2011; 1221: 109-118.

[20] Venetis C.A., Kolibianakis E.M., Toulis K.A. et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil. Steril. 2011; 95 (1): 188-196.

[21] Youssef M.A., Al-Inany H.G., Evers J.L. et al. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2011: 16 (2): CD001302.

[22] Jarzembovska M., Koryntova D., Rezabek K. Ovarian hypertimulation syndrome: a review. Ceska Gynekol. 2007; 72 (1): 52-57.

[23] Kasum M. New insights in mechanisms for development of ovarian hyperstimulation syndrome. Coll. Antropol. 2010; 34 (3): 1139-1143.

[24] Kasum M., Oresković S. Treatment of ovarian hyperstimulation syndrome: new insights. Acta Clin. Croat. 2010; 49 (4): 421-427.

[25] Levick J.R., Michel C.C. Microvascular fl uid exchange and the revised Starling principle. Cardiovasc. Res. 2010; 87 (2): 198-210.

[26] Management of Ovarian Hyperstimulation Syndrome. Royal College of Obstetricians and Gynaecologists. Green-top Guideline. 2006; N 5.

[27] De Backer D., Donadello K., Taccone F.S. et al. Microcirculatory alterations: potential mechanisms and implications for therapy. Ann. Intensive Care. 2011; 19; 1 (1): 27.

[28] Kumar P., Shen Q. et al. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev. Mol. Med. 2009; 11: e19.

[29] Nelson S.M. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thromb. Res. 2013; 131: 1: S1-S3.

[30] Budev M., Arroliga A., Falcone T. Ovarian hyperstimulation syndrome. Crit. Care Med. 2005; 33: 301-306.

[31] Le Gouez A., Naudin B., Grynberg M. et al. Ovarian hyperstimulation syndrome. Ann. Fr. Anesth. Reanim. 2011; 30 (4): 353-362.

[32] Ovarian hyperstimulation syndrome. Practice Committee of the American Society for Reproductive Medicine. Fertil. Steril. 2006; 86 (5 Suppl.): S178- S183.

[33] Kumar P., Sait S.F., Sharma A. et al. Ovarian hyperstimulation syndrome. J. Hum. Reprod. Sci. 2011; 4 (2): 70-75.

[34] Lamazou F., Legouez A., Letouzey V. et al. Ovarian hyperstimulation syndrome: pathophysiology, risk factors, prevention, diagnosis and treatment. J. Gynecol. Obstet. Biol. Reprod. (Paris). 2011; 40 (7): 593-611.

[35] Genazzani A.R., Monteleone P., Papini F. et al. Pharmacotherapy of ovarian hyperstimulation syndrome. Expert Opin. Pharmacother. 2010; 11 (15): 2527-2534.

[36] Gómez R., Soares S.R., Busso C. Physiology and pathology of ovarian hyperstimulation syndrome. Semin. Reprod. Med. 2010; 28 (6): 448-457.

[37] Aljawoan F.Y., Hunt L.P., Gordon U.D. Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. J. Hum. Reprod. Sci. 2012; 5 (1): 32-36.

[38] Chen C.D., Chen S.U., Yang Y.S. Prevention and management of ovarian hyperstimulation syndrome. Best Pract. Res. Clin. Obstetr. Gynaecol. 2012; 26 (6): 817-827.

[39] Schouten M., Wiersinga W.J., Levi M., van der Poll T. Infl ammation, endothelium, and coagulation in sepsis. J. Leukoc Biol. 2008; 83 (3): 536-545.

[40] Curiel Balsera E., Prieto Palomino V.A., Muñoz Bono J. Severe ovarian hyperstimulation syndrome. Med. Clin. (Barc). 2011; 137 (4): 184-185.

[41] Shmorgun D., Claman P.J. The diagnosis and management of ovarian hyperstimulation syndrome. Obstetr. Gynaecol. Can. 2011; 33 (11): 1156-1162.

[42] Tan B.K., Mathur R. Management of ovarian hyperstimulation syndrome. Hum. Fertil. (Camb). 2013.

[43] Jakimiuk A.J., Grzybowski W., Zakrzewski J. et al. The ovarian hyper stimulation syndrome-diagnostic criteria, management proce dures. Ginekol. Pol. 2006; 77 (11): 885-892.

[44] Wei L.H., Chou C.H., Chen M.W. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. J. Clin. Endocrinol. Metab. 2013; 98 (3): E472-E484.

[45] Alatri А., Tribout В., Gencer В. et al. Thrombotic risk in assisted reproductive technology. Rev. Med. Suisse. 2011; 7 (281): 357-360.

[46] Vlahos N.F., Gregoriou O. Prevention and management of ovarian yperstimulation syndrome. Ann. N.Y. Acad. Sci. 2006; 1092: 247-264.

[47] Shannon M.B., Ian A.G., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest - February - 2012; 141: 2.

[48] Woodcock T.E., Woodcock T.M. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. J. Anaesthesia. 2012; 108 (3): 384-394.

[49] Zivi E., Simon A., Laufer N. Ovarian hyperstimulation syndrome: defi nition, incidence, and classifi cation. Semin. Reprod. Med. 2010; 28 (6): 441-447.

RIGHTS & PERMISSIONS

Eco-Vector